Investigational drug · Phase 2
nangibotide
Also called: LR12
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Shock, Septic.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 11, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "nangibotide"
First trial start
2019
Nov 13, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "nangibotide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Shock, Septic
Largest trials
Live from ClinicalTrials.gov: studies naming "nangibotide" as an intervention, largest first.
- Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic ShockPivotal-lookingActive, not recruiting
InotremIndustry
NCT04055909 · 355 participants · Start Nov 13, 2019 · Primary completion May 9, 2022
Drug: nangibotide low dose; nangibotide high dose and 1 more · For: Shock, Septic
Sites: Brussels, Belgium; Genk, Belgium; Ghent, Belgium · 43 sites in all
- Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory SupportPivotal-lookingCompleted
InotremIndustry
NCT04429334 · 220 participants · Start Sep 23, 2020 · Primary completion May 20, 2022
Drug: nangibotide; placebo · For: COVID19
Sites: Brussels, Belgium; Genk, Belgium; Angers, France · 17 sites in all
InotremIndustry
NCT03158948 · 50 participants · Start Jul 3, 2017 · Primary completion Jun 13, 2018
Drug: Nangibotide 0.3 mg/kg; Placebo and 2 more · For: Shock, Septic
Sites: Brussels, Belgium; Limoges, France; Nijmegen, Netherlands · 4 sites in all
- Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male SubjectsCompleted
InotremIndustry
NCT03463044 · 27 participants · Start Apr 1, 2016 · Primary completion Aug 25, 2016
Drug: nangibotide; Placebo · For: Healthy Subjects
Sites: Croydon, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- TREM-1 in Sepsis and Septic Shock: From Pathophysiology to Precision Immunomodulation.
Evrard B, Van Der Poll T, Chousterman B, et al. · Semin Respir Crit Care Med 2026
- Development and Physicochemical Characterization of Trans-Resveratrol Liposomes: Influence of Phospholipid Composition and Ultrasound-Assisted Processing.
Pudžiuvelytu L, Paliulian A · Pharmaceutics 2026
- Climate-Resilient Bread Wheat for Arid Environments: Adaptation and Yield Performance of Diverse Genotypes Across Contrasting Growing Conditions.
Almarri NB, Mansour M, Elwakeel SE, et al. · Plants (Basel) 2026
- TREM1-mediated macrophage activation drives voriconazole-induced hepatic steatosis: Diagnostic and therapeutic implications.
Liu J, Deng M, He X, et al. · J Pharm Anal 2026
- Soluble triggering receptor expressed on myeloid cells-1 as a predictive biomarker in sepsis: insights into cut-offs, mortality risk, and treatment guidance-secondary analysis of the Next GeneSiS-Trial.
Theobald V, Gregorius J, Berger MM, et al. · Crit Care 2026
- Collagen-Enriched Immunomodulatory Hydrogel for Tendon Regeneration.
Patel S, Pan J, Nguyen AP, et al. · Gels 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.